[{"orgOrder":0,"company":"Varsity Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Novobiocin Sodium","moa":"Polymerase theta helicase","graph1":"Oncology","graph2":"Preclinical","graph3":"Varsity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Varsity Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Varsity Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Novobiocin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : VP-006 (Novobiocin), a drug previously used as an antibiotic, is a potent Pol-Theta enzyme inhibitor that can be used alone or in combination with PARP inhibitors to treat HR-deficient tumors, even after they have become resistant to PARP inhibitor thera...

                          Brand Name : VP-006

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 07, 2022

                          Lead Product(s) : Novobiocin Sodium

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank